Literature DB >> 2627962

Acute renal failure after cardiovascular surgery. Current concepts in pathophysiology, prevention and treatment.

P B Leurs1, A W Mulder, H A Fiers, S J Hoorntje.   

Abstract

Acute renal failure (ARF) is a serious complication of cardiovascular surgery and has a high mortality rate, especially with oliguria. It is usually caused by ischaemic injury of the kidney, resulting from inadequate perfusion. Certain risk factors which might lead to the development of ARF following open heart operations have been identified: age greater than 70 years; elevated pre-operative serum creatinine; low blood pressure during cardiopulmonary bypass; rate of haemolysis; a postoperative critical circulation. It is necessary to establish the diagnosis as soon as possible in order to institute corrective measures to prevent oliguric ARF. Once renal failure is established close control of hydration, solutes and potentially toxic metabolites is necessary. Early renal replacement therapy with proper nutritional support appears to improve survival.

Entities:  

Mesh:

Year:  1989        PMID: 2627962     DOI: 10.1093/eurheartj/10.suppl_h.38

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

Review 1.  Pump or no pump for coronary artery bypass: current best available evidence.

Authors:  Shahzad G Raja
Journal:  Tex Heart Inst J       Date:  2005

2.  Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery.

Authors:  F Valsson; S E Ricksten; T Hedner; S Lundin
Journal:  Intensive Care Med       Date:  1996-03       Impact factor: 17.440

Review 3.  Acute renal failure in general surgery.

Authors:  M Slapak
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

4.  ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.

Authors:  Markus Flesch; Stephan Knipp; Gerhard Kessler; Hans-Joachim Geissler; Parwis Massoudy; Hans Wilhelm; Thomas Philipp; Erland Erdmann
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.